Share
629 Posts.
lightbulb Created with Sketch. 33
clock Created with Sketch. 11/01/18
16:20
Share
Originally posted by Fact Finder
↑
There is no doubt that there is a faster path to market as you have said and a high unmet need is an essential criteria. From research I did ages ago another important factor was whether the drug seeking a faster approval had a high adverse event risk. It was also clear that the approval could be conditional and restricted to patients at the end of approved treatment pathways who have little time and no other hope.
Expand
High unmet need. Not sure VLAs clinical programmes address an unmet need, given there are a number of approved i/o products across multiple indications
